SM 030 - DermBiont
Alternative Names: SM-030 - DermBiontLatest Information Update: 26 Jun 2024
At a glance
- Originator James Madison University
- Developer DermBiont
- Class Skin disorder therapies; Small molecules
- Mechanism of Action Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hyperpigmentation; Melanosis